Latest Industry Insights

Technology Networks recently spoke with William J. Golden, Noveome Biotherapeutics’ Founder, Chairman and CEO, who explains the underlying basis for investigating ST266’s potential against COVID-19. Golden also elaborates on many of the other indications for which ST266 is being developed to treat.

Genetic technologies have advanced to the point that digital and experimental approaches can work hand-in-hand. We spoke to Emilie Fritsch, a field application scientist at Synthace, to find out more.

A number of biopharmaceutical industry leaders met in a virtual press conference today to outline progress in COVID-19 vaccine development. Here's what they had to say.

Technology Networks spoke with Jeff Wolf, Heat Biologics CEO, to discuss what vaccine hesitancy is, why it is problematic and the steps that need to be taken to prevent vaccine hesitancy.

Last week, Vaxart announced that it has selected its lead COVID-19 vaccine candidate, and has contracted with KindredBio to manufacture the vaccine in bulk. Technology Networks interviewed Walter Latour, MD, CEO and Chairman of Vaxart, to delve deeper into oral vaccine technology, the preclinical results for the oral candidates for COVID-19 and the next steps in this space.

In facilitating the move to continuous processing in biotherapeutic production, bioprocessing specialists are being driven to develop innovative analytical testing methods for key measurements of output and quality, such as antibody titer.

Technology Networks recently spoke with Nick Milne, co-founder and CSO at Octarine to learn more about what science says on the therapeutic benefits of psychedelic compounds, why a bio-based approach for manufacturing is advantageous and the challenges associated.

Advances in developing cell-based therapeutics and products require time-consuming and laborious cell-by-cell manipulation and analysis. Berkeley Lights Inc provide research and development services to help accelerate this process and make it more efficient via their proprietary technology. Technology Networks recently spoke with Mark White, Sr. Director of Marketing, Berkeley Lights Inc to find out more.

The UK registered and self-funding charity LifeArc has several antibody–drug conjugate (ADC) programs in the oncology and non-oncology space. Technology Networks recently had the pleasure of speaking with Dr Laura Murch, Scientist at LifeArc, to learn more about ADCs. She highlights some of the antibody characterization assays they have developed to identify candidate ADCs, and touches on the regulatory success of ADCs.

Jagannath Swaminathan is the co-founder of Erisyon and a researcher at the Marcotte Lab at the University of Texas Austin. In this interview, we discuss the concept of next-generation protein sequencing, clinical proteomics and the critical role of protein sequencing in the fight against COVID-19.